tradingkey.logo

Mabwell Announces Novel Drug Technology License Agreement With Qilu Pharmaceutical For Albipagrastim Alfa For Injection

ReutersJun 27, 2025 2:20 PM

- Mabwell Shanghai Bioscience Co Ltd 688062.SS:

  • MABWELL ANNOUNCES NOVEL DRUG TECHNOLOGY LICENSE AGREEMENT WITH QILU PHARMACEUTICAL FOR ALBIPAGRASTIM ALFA FOR INJECTION

  • MABWELL SHANGHAI BIOSCIENCE - QILU PHARMACEUTICAL GRANTED EXCLUSIVE RIGHTS FOR LICENSED PRODUCT IN GREATER CHINA

  • MABWELL SHANGHAI BIOSCIENCE CO LTD - T-MAB TO RECEIVE UP TO RMB 500 MILLION IN PAYMENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI